trans-2,3b,4,5,7,8b,9,10-Octahydronaphtho[1,2-c:5,6-c']dipyrazole, a new orally active antiallergic compound.
The synthesis and antiallergic activity of a new heterocyclid steroidal molecule are described. Compound 1 was shown to inhibit the rat passive cutaneous anaphylaxis and its activity in this system was compared to that of disodium cromoglycate. It is orally active at a dose of 35 mg/kg (ED50) and its activity persists for up to 6 h for larger doses.